Cargando…

Clinical and genetic associations with prostacyclin response in pulmonary arterial hypertension

Parenteral prostacyclin therapy is the most efficacious pharmacologic treatment for pulmonary arterial hypertension (PAH), but clinical response is variable. We sought to identify clinical, hemodynamic, and genetic associations with response to prostacyclin therapy. We performed a retrospective anal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Halliday, Stephen J., Xu, Meng, Thayer, Timothy E., Mosley, Jonathan D., Sheng, Quanhu, Ye, Fei, Farber-Eger, Eric H., Pugh, Meredith E., Robbins, Ivan R., Assad, Tufik R., West, James D., Brittain, Evan L., Hemnes, Anna R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134494/ https://www.ncbi.nlm.nih.gov/pubmed/30142026 http://dx.doi.org/10.1177/2045894018800544

Ejemplares similares

Lack of a Tricuspid Regurgitation Doppler Signal and Pulmonary Hypertension by Invasive Measurement
por: O'Leary, Jared M., et al.
Publicado: (2018)

Echocardiographic Detection of Occult Diastolic Dysfunction in Pulmonary Hypertension After Fluid Challenge
por: Agrawal, Vineet, et al.
Publicado: (2019)

Pulmonary hypertension in patients with chronic kidney disease: invasive hemodynamic etiology and outcomes
por: O’Leary, Jared M., et al.
Publicado: (2017)

Racial differences in patients referred for right heart catheterization and risk of pulmonary hypertension
por: Yang, Bin Q., et al.
Publicado: (2018)

Hemodynamic Improvement of Pulmonary Arterial Hypertension After Bariatric Surgery: Potential Role for Metabolic Regulation
por: Pugh, Meredith E., et al.
Publicado: (2013)

An algorithm to identify cases of pulmonary arterial hypertension from the electronic medical record
por: Schuler, Kyle P., et al.
Publicado: (2022)

Predictors of Diastolic-To-Wedge Gradient in Patients Evaluated for Pulmonary Hypertension
por: Brittain, Evan L., et al.
Publicado: (2013)

Using genetics to detangle the relationships between red cell distribution width and cardiovascular diseases: a unique role for body mass index
por: Thayer, Timothy E, et al.
Publicado: (2021)

Reduced free-living activity levels in pulmonary arterial hypertension patients
por: Halliday, Stephen J., et al.
Publicado: (2018)

Sex hormone exposure and reproductive factors in pulmonary arterial hypertension: a case–control study
por: Badlam, Jessica B., et al.
Publicado: (2020)

Mechanistic Phase II Clinical Trial of Metformin in Pulmonary Arterial Hypertension
por: Brittain, Evan L., et al.
Publicado: (2020)

Use of prostacyclin in pulmonary hypertension
por: Vicente, R, et al.
Publicado: (1998)

Role of prostacyclin in pulmonary hypertension
por: Mitchell, Jane A., et al.
Publicado: (2014)

The transpulmonary ratio of endothelin 1 is elevated in patients with preserved left ventricular ejection fraction and combined pre- and post-capillary pulmonary hypertension
por: Meoli, David F., et al.
Publicado: (2017)

Clinical features do not identify risk of progression from isolated postcapillary pulmonary hypertension to combined pre‐ and postcapillary pulmonary hypertension
por: Babu, Gautam, et al.
Publicado: (2023)

Evidence of pulmonary arterial hypertension in two patients with common variable immunodeficiency
por: Huston, Jessica, et al.
Publicado: (2020)

Practical considerations for therapies targeting the prostacyclin pathway
por: Farber, Harrison W., et al.
Publicado: (2016)

Identifying “super responders” in pulmonary arterial hypertension
por: Halliday, Stephen J., et al.
Publicado: (2017)

Combination Therapy in Pulmonary Arterial Hypertension—Targeting the Nitric Oxide and Prostacyclin Pathways
por: Mandras, Stacy, et al.
Publicado: (2021)

Peak steps: Capacity for activity improves after adding approved therapy in pulmonary arterial hypertension
por: Lachant, Daniel, et al.
Publicado: (2023)

Subdural hematomas in pulmonary arterial hypertension patients treated with prostacyclin analogs
por: Louis, Lam, et al.
Publicado: (2012)

Prostacyclin Regulation of Allergic Inflammation
por: Patel, Kunj, et al.
Publicado: (2022)

Mendelian randomisation analysis of red cell distribution width in pulmonary arterial hypertension
por: Ulrich, Anna, et al.
Publicado: (2020)

Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension
por: Lang, Irene M., et al.
Publicado: (2015)

Hypochloremia Is a Noninvasive Predictor of Mortality in Pulmonary Arterial Hypertension
por: Prins, Kurt W., et al.
Publicado: (2020)

Hemodynamic assessment of transitioning from parenteral prostacyclin to selexipag in pediatric pulmonary hypertension
por: Colglazier, Elizabeth, et al.
Publicado: (2022)

Elicitation of health state utilities associated with the mode of administration of drugs acting on the prostacyclin pathway in pulmonary arterial hypertension
por: Davies, Evan W, et al.
Publicado: (2018)

PROSTACYCLIN IN HEALTH AND DISEASE
Publicado: (1983)

Prostacyclin: An Inflammatory Paradox
por: Stitham, Jeremiah, et al.
Publicado: (2011)

Prostacyclin Synthesis and Prostacyclin Receptor Expression in the Porcine Myometrium: Prostacyclin Potential to Regulate Fatty Acid Transporters, Cytokines and Contractility-Related Factors
por: Blitek, Agnieszka, et al.
Publicado: (2022)

Management of prostacyclin side effects in adult patients with pulmonary arterial hypertension
por: Kingman, Martha, et al.
Publicado: (2017)

A potential adverse role for leptin and cardiac leptin receptor in the right ventricle in pulmonary arterial hypertension: effect of metformin is BMPR2 mutation-specific
por: Talati, Megha, et al.
Publicado: (2023)

Adverse physiologic effects of Western diet on right ventricular structure and function: role of lipid accumulation and metabolic therapy
por: Brittain, Evan L., et al.
Publicado: (2018)

Impact of additional selexipag on prostacyclin infusion analogs in patients with pulmonary arterial hypertension
por: Momoi, Mizuki, et al.
Publicado: (2022)

Natriuretic peptide receptor C contributes to disproportionate right ventricular hypertrophy in a rodent model of obesity-induced heart failure with preserved ejection fraction with pulmonary hypertension
por: Agrawal, Vineet, et al.
Publicado: (2019)

An organ-on-chip model of pulmonary arterial hypertension identifies a BMPR2-SOX17-prostacyclin signalling axis
por: Ainscough, Alexander J., et al.
Publicado: (2022)

Glyoxylase-1 combats dicarbonyl stress and right ventricular dysfunction in rodent pulmonary arterial hypertension
por: Prisco, Sasha Z., et al.
Publicado: (2022)

Right ventricular function mirrors clinical improvement with use of prostacyclin analogues in pediatric pulmonary hypertension
por: Hopper, Rachel K., et al.
Publicado: (2018)

Transpulmonary generation of cell‐free hemoglobin contributes to vascular dysfunction in pulmonary arterial hypertension via dysregulated clearance mechanisms
por: Meegan, Jamie E., et al.
Publicado: (2023)

A multifaceted investigation into molecular associations of chronic thromboembolic pulmonary hypertension pathogenesis
por: Halliday, Stephen J, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_12oj62dc6u5f2l1dc7t8jh2dc5